In 2026, the women’s health trial pipeline is more active than at any prior point — driven by GnRH antagonist combinations for endometriosis and fibroids, GLP-1 agonist data in PCOS, non-surgical uterine fibroid approaches, and novel endometriosis targets that go beyond estrogen suppression.
Categories